Conference Reports for NATAP

Back

Digestive Disease Week May 18-21, 2024 Washington, D.C.     TO DETERMINE THE TRANSIENT ELASTOGRAPHY CUT-OFF FOR ADVANCED FIBROSIS IN CHRONIC HEPATITIS B PATIENTS WITH CONCUEERNT HEPATIC STEATOSIS - (05/21/24)   LONG-TERM SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS - FINAL 8-YEAR RESULTS OF 2 PHASE 3 STUDIES - (05/21/24)   Metabolics Linked to Increased Risk of Liver & Non-Liver Complications in HBV+ - (05/21/24)   LONG-TERM EFFICACY OF TENOFOVIR ALAFENAMIDE IN HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED FOR UP TO 8 YEAR IN 2 PHASE 3 STUDIES - (05/21/24)   COMBATING HEPATITIS C IN MISSOURI: PUBLIC-PRIVATE PARTNERSHIP WITH LOCAL PUBLIC HEALTH AGENCIES TO ERADICATE HCV IN MISSOURI - (05/21/24)   HCV+ Organ transplants Successful 98% Cure Rate: HEPATITIS C TREATMENT AFTER SOLID ORGAN TRANSPLANT IS EFFECTIVE USING ANY DAA REGIMEN AND DOES NOT NEGATIVELY IMPACT REJECTION RATES OR GRAFT FUNCTION - (05/21/24)   SGLT2I REDUCES THE RISK OF DEVELOPING HCC IN PATIENTS WITH CO-EXISTING HEPATITIS C INFECTION AND TYPE 2 DIABETES: A GLOBAL MULTICENTER PROPENSITY-MATCHED STUDY - (05/21/24)   CHECKING IS LACKING: SUBOPTIMAL SURVEILLANCE [38%] FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH SUSTAINED VIROLOGIC RESPONSE AFTER DIRECT-ACTING ANTIVIRAL THERAPY FOR HEPATITIS C....GI/liver specialty clinics provided better surveillance - (05/21/24)   HCC Rates Predicted Black Disparities Widening 33% by 2028 USA - (05/21/24)   HIDDEN LINK BETWEEN HEPATITIS C INFECTION AND HEPATOCELLULAR CARCINOMA IN NON-CIRRHOTIC PATIENTS: A NATIONAL INPATIENT SAMPLE ANALYSIS - (05/21/24)   Delayed Diagnosis of HCV - Results of Nationwide US Study - (05/21/24)   HEPATITIS B VERSUS HEPATITIS B DELTA CO-INFECTION AND RISK OF HEPATOCELLULAR CARCINOMA IN NON-CIRRHOTIC LIVER - (05/21/24)   HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301 - (05/21/24)   NON-INVASIVE TESTING IN CHRONIC HEPATITIS D VIRUS (HDV) INFECTION: WHAT WORKS BEST TO RULE OUT CIRRHOSIS? - (05/21/24)   EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY - (05/21/24)   PERCEPTIONS OF QUALITY OF LIFE, FATIGUE AND HEALTH OUTCOMES IN CHRONIC LIVER DISEASE PATIENTS - (05/20/24)   DE NOVO HEPATOCELLULAR CARCINOMA (HCC) IN NON-CIRRHOTIC CHRONIC VIRAL HEPATITIS C (HCV) PATIENTS: A CASE SERIES - (05/20/24)   THERE IS A PERSISTENT GAP IN THE QUALITY OF TIMELY HEPATITIS C ERADICATION DESPITE EFFORTS TO STREAMLINE SPECIALIST REFERRALS FROM PRIMARY CARE - (05/20/24)   PREDICTORS OF THE RECEIPT OF HEPATITIS C VIRUS (HCV) TREATMENT AMONG CURRENT PATIENTS IN A LARGE URBAN HEALTHCARE SYSTEM - (05/20/24)   MORTALITY RATES AMONG PATIENTS SUCCESSFULLY TREATED FOR HEPATITIS C: A REAL WORLD MULTINATIONAL COHORT STUDY - (05/20/24)   HEPATITIS C RESURGENCE IN THE U.S: A DETAILED STUDY OF INCIDENCE AND MORTALITY TRENDS (1990-2019) - (05/20/24)